替莫唑胺联合放疗对胶质瘤患者VEGF、IL-8表达的影响

发布时间：2018-05-29 01:59

本文选题：替莫唑胺 + 放疗　；参考：《基因组学与应用生物学》2016年12期

【摘要】：为研究替莫唑胺联合放疗对胶质瘤患者血管内皮生长因子(VEGF)、白介素-8(IL-8)表达的影响,本研究选取2010年7月至2011年6月我院收治的60例胶质瘤患者,根据随机抽签法分为试验组和对照组,每组30例。对照组使用放疗方式,试验组患者在此基础上口服替莫唑胺,150 mg·m~(-2)·d~(-1),连续服用5 d,4周为1个治疗周期,根据患者具体情况给药4~6个周期。比较两组患者治疗前后VEGF、IL-8水平、生活质量改善情况,评判两组患者的临床疗效、生存率、不良反应。结果显示,治疗后,试验组的总有效率86.67%(26/30)显著高于对照组63.33%(19/30),差异有统计学意义(p0.05)。试验组的VEGF、IL-8水平显著低于对照组,(65.93±3.55)pg/m L比(85.85±3.26)pg/m L,(20.81±1.92)pg/m L比(31.11±3.10)pg/m L(p0.05);试验组的KPS评分明显高于对照组,(83.06±5.16)分比(71.34±2.82)分(p0.05);试验组1年、2年、3年的生存率显著高于对照组,90.00%(27/30)比73.33%(22/30),80.00%(24/30)比50.00%(15/30),66.67%(20/30)比36.67%(11/30);中位复发时间晚于对照组,(24.32±2.32)月比(16.23±1.45)月,差异均有统计学意义(p0.05);试验组和对照组的不良反应率比较无显著性差异,16.67%(5/30)比20.00%(6/30)(p0.05)。研究结果表明替莫唑胺联合放疗能明显降低胶质瘤患者VEGF、IL-8表达,临床疗效良好,可提高患者的生活质量和生存率,安全性高。
[Abstract]:To study the effect of Temozolomide Combined with radiotherapy on the expression of vascular endothelial growth factor (VEGF) and interleukin (IL-8) -8 (IL-8) in patients with glioma, 60 patients with glioma treated in our hospital from July 2010 to June 2011 were selected and divided into experimental and control groups, with 30 cases in each group. The control group was treated with radiotherapy, and the patients in the test group were in the test group. On this basis, the oral temozolomide, 150 mg. M~ (-2) / d~ (-1), continuous taking 5 d, 4 weeks for 1 period of treatment, according to the specific situation of the patient to give 4~6 cycles. Compare the two groups of patients before and after treatment VEGF, IL-8 level, quality of life improvement, evaluation of two groups of patients in bed effect, survival, adverse reactions. The results showed, after treatment, experimental group. Results showed after treatment, experimental group. Results showed after treatment, experimental group. Results showed after treatment, experimental group. The total effective rate of 86.67% (26/30) was significantly higher than that of the control group (19/30), and the difference was statistically significant (P0.05). The level of VEGF, IL-8 in the experimental group was significantly lower than that of the control group (65.93 + 3.55) pg/m L ratio (85.85 + 3.26) pg/m L, (20.81 + 1.92) pg/m L ratio (31.11 + 3.10), and the test group was significantly higher than the control group (83.06 + 5.16) ratio (7) 1.34 + 2.82) score (P0.05); the survival rate of the experimental group for 1 years, 2 years and 3 years was significantly higher than that of the control group, 90% (27/30), 73.33% (22/30), 80% (24/30), 50% (15/30) and 66.67% (20/30) ratio 36.67% (11/30); the median recurrence time was later than that of the control group (24.32 + 2.32) months, the difference was statistically significant (P0.05); the experimental group and the control group. There was no significant difference in the rate of adverse reaction between 16.67% (5/30) and 20% (6/30) (P0.05). The results showed that the combined radiotherapy of temozolomide could obviously reduce the expression of VEGF and IL-8 in the patients with glioma, and the clinical effect was good, and it could improve the life quality and survival rate of the patients with high safety.
【作者单位】：西南医科大学;西南医科大学附属中航工业三六三医院神经外科;
【基金】：四川省科技厅基金(2011F20032)资助
【分类号】：R739.41

【相似文献】